Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.

Leerink Global Healthcare Conference 2026 March 10, 2026 1:00 PM EDTCompany ParticipantsHelen Torley - President, ...

I’ve had countless skin issues over the years, and I’m no stranger to the seemingly never-ending cycle of spending money on remedies, products and treatments, only to have so many of them not work for ...

CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...